Emerging technologies such as artificial intelligence have attracted wide attention in the field of new drug research and development, and concepts such as "virtual clinical trial" have emerged one after another. On November 2, at the new drug research and Development Forum of the world's top scientists, the world's top scientists talked about a new chapter in pharmacy. Aliyah Vasher, the winner of the 2013 Nobel prize in chemistry, focused on the key role of computer technology in COVID-19 and the pharmaceutical industry: "now we have enormous computing power to solve many problems that we could not solve before." Taking COVID-19 as an example, in June last year, Watts and his team calculated the possibility of virus mutation through computational research methods, and did some research before the real mutation occurred. For drug research and development, computers can also be used to calculate the binding affinity of drugs. Yang Zhantao, Deputy Secretary General of the World Association of top scientists and senior scientist of the International Joint Laboratory of the world's top scientists, mentioned the application of artificial intelligence in new drug research and development. Whether it is biological research or pharmaceutical discovery, it is not just about numbers, but about the real efficacy, function, effect, and whether drugs are harmful to patients. "Artificial intelligence is very hot now, especially in the past three years, it is a fire field." according to Jiang Hualiang, academician of the Chinese Academy of Sciences, artificial intelligence is only a new technology, and we should use it very carefully. "Artificial intelligence is just an advanced technology, which can shorten the time of drug development, or help clinical trials collect clinical data, establish models, and then predict whether drugs can succeed. We may be able to do it within five years." meanwhile, Jiang Hualiang also said that it is still a problem in actual clinical trials, Because clinical experiments should be carried out in the human body, not artificial intelligence. "Clinical trials should be conducted in the human body, not artificial intelligence." academician Jiang Hualiang and Wang Xingli, head of Novartis global drug development department (China), also stressed the subjective position of human beings in clinical trials. Although he saw the cutting-edge application of machine learning in clinical research in IBM laboratory a few years ago, Wang Xingli still said that artificial intelligence can not replace real human clinical trials. One drug will not apply to all patients, so how can patients benefit? Ten thousand of the millions of compounds may be the last drug, but its receptors may be suitable for only a small population. "In the process of clinical trials, due to the small sample size, we need to calculate how the drugs are in a large number of other patients through artificial intelligence. How can we modify our rules for recruiting receptors in clinical trials? Artificial intelligence can help us in this point, which can improve the specificity of drugs and shorten the opening time of drugs "Hair cycle," said Wang Xingli. (Xinhua News Agency)